Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26645498 | 1.00 | LMNA (0.33) | LMNAPOLBATMALDH1A1MEN1 | |
| SCHEMBL7869373 | 0.93 | ATM (0.42) | LMNAPOLBATMALDH1A1MEN1 | |
| SCHEMBL7869371 | 0.93 | ATM (0.42) | LMNAPOLBATMALDH1A1MEN1 | |
| SCHEMBL27956339 | 0.89 | HPGD (0.31) | LMNAPOLBALDH1A1HPGD | |
| SCHEMBL9790250 | 0.87 | ATM (0.41) | POLBATMMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9790252 | 0.87 | ATM (0.41) | POLBATMMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL17695738 | 0.86 | HCAR2 (0.43) | LMNAALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL26750612 | 0.85 | — | — | |
| SCHEMBL61154 | 0.84 | LMNA (0.32) | LMNAPOLBALDH1A1MEN1KMT2A | |
| SCHEMBL21891529 | 0.84 | MEN1 (0.32) | LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382880-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2023-11-30 | — | — | US | disclosed |
| US-20230382851-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2023-11-30 | — | — | US | disclosed |
| US-20230382851-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2023-11-30 | — | — | US | disclosed |
| US-20230382881-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2023-11-30 | — | — | US | disclosed |
| US-20230382881-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2023-11-30 | — | — | US | disclosed |
| US-20230382880-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2023-11-30 | — | — | US | disclosed |
| WO-2023205245-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ZEVRA THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230338543-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2023-10-26 | — | — | US | disclosed |
| WO-2023205241-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ZEVRA THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205237-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ZEVRA THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230338543-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2023-10-26 | — | — | US | disclosed |
| WO-2023205233-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ZEVRA THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-6306990-B1 | MALEIC ACID DIESTER MONOMERS FOR POLYMER FILMS AND HEAT STABLE POLYMERS | SIEMENS AKTIENGESELLSCHAFT (DE) | 2001-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382881-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | HSD17B10, HSD17B12, HSD17B14 | LMNA 2600/4885POLB 359/4885ATM 3181/4885 |
| US-20230382880-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | HSD17B10, HSD17B12, HSD17B14 | LMNA 2600/4885POLB 359/4885ATM 3181/4885 |
| US-20230338543-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | HSD17B10, HSD17B12, HSD17B14 | LMNA 2652/4885POLB 417/4885ATM 3956/4885 |
| US-20230382851-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | HSD17B10, HSD17B12, HSD17B14 | LMNA 2600/4885POLB 359/4885ATM 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.